Global Painful Bladder Syndrome (Interstitial Cystitis) Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets
High levels of pipeline activity are being observed in Painful Bladder Syndrome (Interstitial Cystitis) treatment during 2019. Clinical development activities are being undertaken by more than 10 companies including Alivio Therapeutics Inc , Astellas Pharma Inc, GlycoMira Therapeutics Inc, Idera Pharmaceuticals Inc, Kyorin Pharmaceutical Co Ltd and others.
A Significant contribution to the Painful Bladder Syndrome (Interstitial Cystitis) pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Painful Bladder Syndrome (Interstitial Cystitis) pipeline included 11 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Painful Bladder Syndrome (Interstitial Cystitis) condition and increased access to investments is encouraging growth of Painful Bladder Syndrome (Interstitial Cystitis) drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Painful Bladder Syndrome (Interstitial Cystitis) drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Painful Bladder Syndrome (Interstitial Cystitis) therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Painful Bladder Syndrome (Interstitial Cystitis) pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Painful Bladder Syndrome (Interstitial Cystitis). Further, orphan drug status, fast track designation, grants awarded and other special status for Painful Bladder Syndrome (Interstitial Cystitis) pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Painful Bladder Syndrome (Interstitial Cystitis) pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Painful Bladder Syndrome (Interstitial Cystitis) Pipeline candidates-
A Significant contribution to the Painful Bladder Syndrome (Interstitial Cystitis) pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Painful Bladder Syndrome (Interstitial Cystitis) pipeline included 11 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Painful Bladder Syndrome (Interstitial Cystitis) condition and increased access to investments is encouraging growth of Painful Bladder Syndrome (Interstitial Cystitis) drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Painful Bladder Syndrome (Interstitial Cystitis) drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Painful Bladder Syndrome (Interstitial Cystitis) therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Painful Bladder Syndrome (Interstitial Cystitis) pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Painful Bladder Syndrome (Interstitial Cystitis). Further, orphan drug status, fast track designation, grants awarded and other special status for Painful Bladder Syndrome (Interstitial Cystitis) pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Painful Bladder Syndrome (Interstitial Cystitis) pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Painful Bladder Syndrome (Interstitial Cystitis) Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Painful Bladder Syndrome (Interstitial Cystitis) drugs
- Late phase: Phase 3 and in-approval Painful Bladder Syndrome (Interstitial Cystitis) drugs
- Company overview
- Snapshot
- Painful Bladder Syndrome (Interstitial Cystitis) therapeutic treatment activities
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Painful Bladder Syndrome (Interstitial Cystitis)- Disease Overview
2.2 Painful Bladder Syndrome (Interstitial Cystitis)- Pipeline Snapshot
2.3 Painful Bladder Syndrome (Interstitial Cystitis)- Pipeline Drugs by Phase
2.4 Painful Bladder Syndrome (Interstitial Cystitis)- Pipeline Drugs by Company
2.5 Painful Bladder Syndrome (Interstitial Cystitis)- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Alivio Therapeutics Inc Painful Bladder Syndrome (Interstitial Cystitis) Drug Pipeline, H2- 2019
3.2 Astellas Pharma Inc Painful Bladder Syndrome (Interstitial Cystitis) Drug Pipeline, H2- 2019
3.3 GlycoMira Therapeutics Inc Painful Bladder Syndrome (Interstitial Cystitis) Drug Pipeline, H2- 2019
3.4 Idera Pharmaceuticals Inc Painful Bladder Syndrome (Interstitial Cystitis) Drug Pipeline, H2- 2019
3.5 Kyorin Pharmaceutical Co Ltd Painful Bladder Syndrome (Interstitial Cystitis) Drug Pipeline, H2- 2019
3.6 Lipella Pharmaceuticals Inc Painful Bladder Syndrome (Interstitial Cystitis) Drug Pipeline, H2- 2019
3.7 Mirae Cell Bio Co Ltd Painful Bladder Syndrome (Interstitial Cystitis) Drug Pipeline, H2- 2019
3.8 Pierre Fabre Pharmaceuticals Inc Painful Bladder Syndrome (Interstitial Cystitis) Drug Pipeline, H2- 2019
3.9 UCB SA Painful Bladder Syndrome (Interstitial Cystitis) Drug Pipeline, H2- 2019
3.10 Urigen Pharmaceuticals Inc Painful Bladder Syndrome (Interstitial Cystitis) Drug Pipeline, H2- 2019
3.11 Xigen SA Painful Bladder Syndrome (Interstitial Cystitis) Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Painful Bladder Syndrome (Interstitial Cystitis)- Phase 1 Drug Details
4.2 Painful Bladder Syndrome (Interstitial Cystitis)- Phase 1 Drug Overview
4.3 Painful Bladder Syndrome (Interstitial Cystitis)- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Painful Bladder Syndrome (Interstitial Cystitis)- Phase 2 Drug Details
5.2 Painful Bladder Syndrome (Interstitial Cystitis)- Phase 2 Drug Overview
5.3 Painful Bladder Syndrome (Interstitial Cystitis)- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Painful Bladder Syndrome (Interstitial Cystitis)- Phase 3 Drug Details
6.2 Painful Bladder Syndrome (Interstitial Cystitis)- Phase 3 Drug Overview
6.3 Painful Bladder Syndrome (Interstitial Cystitis)- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Painful Bladder Syndrome (Interstitial Cystitis)- Pre-clinical Phase Drug Details
7.2 Painful Bladder Syndrome (Interstitial Cystitis)- Pre-clinical Phase Drug Overview
7.3 Painful Bladder Syndrome (Interstitial Cystitis)- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Painful Bladder Syndrome (Interstitial Cystitis)- Disease Overview
2.2 Painful Bladder Syndrome (Interstitial Cystitis)- Pipeline Snapshot
2.3 Painful Bladder Syndrome (Interstitial Cystitis)- Pipeline Drugs by Phase
2.4 Painful Bladder Syndrome (Interstitial Cystitis)- Pipeline Drugs by Company
2.5 Painful Bladder Syndrome (Interstitial Cystitis)- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Alivio Therapeutics Inc Painful Bladder Syndrome (Interstitial Cystitis) Drug Pipeline, H2- 2019
3.2 Astellas Pharma Inc Painful Bladder Syndrome (Interstitial Cystitis) Drug Pipeline, H2- 2019
3.3 GlycoMira Therapeutics Inc Painful Bladder Syndrome (Interstitial Cystitis) Drug Pipeline, H2- 2019
3.4 Idera Pharmaceuticals Inc Painful Bladder Syndrome (Interstitial Cystitis) Drug Pipeline, H2- 2019
3.5 Kyorin Pharmaceutical Co Ltd Painful Bladder Syndrome (Interstitial Cystitis) Drug Pipeline, H2- 2019
3.6 Lipella Pharmaceuticals Inc Painful Bladder Syndrome (Interstitial Cystitis) Drug Pipeline, H2- 2019
3.7 Mirae Cell Bio Co Ltd Painful Bladder Syndrome (Interstitial Cystitis) Drug Pipeline, H2- 2019
3.8 Pierre Fabre Pharmaceuticals Inc Painful Bladder Syndrome (Interstitial Cystitis) Drug Pipeline, H2- 2019
3.9 UCB SA Painful Bladder Syndrome (Interstitial Cystitis) Drug Pipeline, H2- 2019
3.10 Urigen Pharmaceuticals Inc Painful Bladder Syndrome (Interstitial Cystitis) Drug Pipeline, H2- 2019
3.11 Xigen SA Painful Bladder Syndrome (Interstitial Cystitis) Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Painful Bladder Syndrome (Interstitial Cystitis)- Phase 1 Drug Details
4.2 Painful Bladder Syndrome (Interstitial Cystitis)- Phase 1 Drug Overview
4.3 Painful Bladder Syndrome (Interstitial Cystitis)- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Painful Bladder Syndrome (Interstitial Cystitis)- Phase 2 Drug Details
5.2 Painful Bladder Syndrome (Interstitial Cystitis)- Phase 2 Drug Overview
5.3 Painful Bladder Syndrome (Interstitial Cystitis)- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Painful Bladder Syndrome (Interstitial Cystitis)- Phase 3 Drug Details
6.2 Painful Bladder Syndrome (Interstitial Cystitis)- Phase 3 Drug Overview
6.3 Painful Bladder Syndrome (Interstitial Cystitis)- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Painful Bladder Syndrome (Interstitial Cystitis)- Pre-clinical Phase Drug Details
7.2 Painful Bladder Syndrome (Interstitial Cystitis)- Pre-clinical Phase Drug Overview
7.3 Painful Bladder Syndrome (Interstitial Cystitis)- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
